STAGE II URETER CANCER AJCC V7
Clinical trials for STAGE II URETER CANCER AJCC V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE II URETER CANCER AJCC V7 trials appear
Sign up with your email to follow new studies for STAGE II URETER CANCER AJCC V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy after bladder cancer surgery may extend lives
Disease control OngoingThis Phase 3 trial tests whether the immunotherapy drug pembrolizumab, given after surgery, helps people with muscle-invasive or locally advanced bladder cancer live longer without the cancer returning. About 739 participants are randomly assigned to receive pembrolizumab or just…
Matched conditions: STAGE II URETER CANCER AJCC V7
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
Immunotherapy combo shows promise for tough bladder cancer cases
Disease control OngoingThis early-phase study tests two immunotherapy drugs (durvalumab and tremelimumab) given before surgery to people with muscle-invasive bladder cancer who cannot receive standard chemotherapy. The goal is to see if the drugs are safe and can shrink tumors or boost the immune syste…
Matched conditions: STAGE II URETER CANCER AJCC V7
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:49 UTC